Bhavana Kunkalikar

Bhavana Kunkalikar

Bachelor of Pharmacy

Pharmaceutical Sciences, Pathophysiology

Bhavana Kunkalikar is a medical writer based in Goa, India. Her academic background is in Pharmaceutical sciences and she holds a Bachelor's degree in Pharmacy. Her educational background allowed her to foster an interest in anatomical and physiological sciences. Her college project work based on ‘The manifestations and causes of sickle cell anemia’ formed the stepping stone to a life-long fascination with human pathophysiology.

See more

After completing her Bachelor’s degree, she gained considerable industrial experience in the maintenance and upkeep of finished retention samples and testing of water samples from across the manufacturing facility. However, in the wake of the pandemic, her passion for scientific writing urged her to take up more writing projects. She is now a full-time content writer at a digital marketing agency in Bengaluru, India. Her pursuit to expand her horizons led her to medical writing that allowed her to amalgamate her passion for writing with her academic background.  

Her childhood dream of becoming a writer, rooted in the fascination with fairy tales and mystery thrillers, led her to play the part of the College Magazine Secretary and undertake the responsibilities of editor-in-chief. This encouraged her to participate in various college-level story writing competitions and win a handful of them, resulting in some of her first pieces of fictional write-ups.

Outside of work, she is interested in reading and writing fiction, with Stephen King being her go-to writer to read and she aspires to discover and read more writers from the technical field. She also plays the keyboard for pleasure and is admittedly bad at it.

See less

Articles from Bhavana

COVID-19 infections during the Omicron wave in unvaccinated US adults

COVID-19 infections during the Omicron wave in unvaccinated US adults

Infection rates and immunological responses to SARS-CoV-2 infection among migrant workers

Infection rates and immunological responses to SARS-CoV-2 infection among migrant workers

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Evaluating tixagevimab plus cilgavimab against SARS-CoV-2

Study investigates whether people with breakthrough SARS-CoV-2 infection develop post-acute sequelae

Study investigates whether people with breakthrough SARS-CoV-2 infection develop post-acute sequelae

Researchers investigate COVID-19 mortality among introverts and extroverts

Researchers investigate COVID-19 mortality among introverts and extroverts

Study evaluates waning levels of protection against SARS-CoV-2 infection among recovered persons and uninfected BNT162b2 vaccinees

Study evaluates waning levels of protection against SARS-CoV-2 infection among recovered persons and uninfected BNT162b2 vaccinees

Study assesses the safety of breastfeeding during maternal SARS-CoV-2 infection

Study assesses the safety of breastfeeding during maternal SARS-CoV-2 infection

Nanotechnology enhanced DNA-chip for SARS-CoV-2 detection with variant differentiation

Nanotechnology enhanced DNA-chip for SARS-CoV-2 detection with variant differentiation

Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity

Study measures viral antigen and inflammatory biomarkers in CSF of COVID-19 patients in relation to neurologic symptoms and disease severity

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.